Skip to Content

Hemato, Volume 3, Issue 4

2022 December - 13 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (13)

  • Case Report
  • Open Access
1 Citations
3,426 Views
8 Pages

Abdominal Lymphadenopathy: Hypothesize Cat-Scratch Disease and Avoid Abdominal Excisional Biopsy

  • Valeria Filipponi,
  • Stefania Trasarti,
  • Francesca Maccioni,
  • Maddalena Zippi,
  • Ludovica Busato,
  • Francesca Arienzo,
  • Mario Biglietto,
  • Paolina Saullo,
  • Carla Giordano and
  • Roberto Caronna

7 December 2022

The finding of lymphadenopathy is usually the consequence of a benign infection, although a neoplastic origin must always be excluded. Through a careful anamnesis, physical examination, and serological tests several differential diagnoses are frequen...

  • Review
  • Open Access
5 Citations
15,743 Views
13 Pages

Bing–Neel Syndrome: Update on Diagnosis and Treatment

  • Evangeline Y. Wong,
  • Shirley D’Sa,
  • Monique C. Minnema,
  • Jorge J. Castillo and
  • Dipti Talaulikar

29 November 2022

Bing–Neel syndrome (BNS) is a rare neurological complication of Waldenström macroglobulinaemia. We highlight key issues in clinical presentation, diagnosis, and treatment while focusing on new and emerging therapies available for patients...

  • Review
  • Open Access
3 Citations
11,704 Views
16 Pages

TP53 Mutant Acute Myeloid Leukemia: The Immune and Metabolic Perspective

  • Federico Zingarelli,
  • Letizia Zannoni and
  • Antonio Curti

15 November 2022

TP53 mutated/deleted acute myeloid leukemia (AML) stands out as one of the poorest prognosis forms of acute leukemia with a median overall survival not reaching one year in most cases, even in selected cases when allogenic stem-cell transplantation i...

  • Article
  • Open Access
1 Citations
7,375 Views
11 Pages

IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis

  • Shayna Sarosiek,
  • Andrew R. Branagan,
  • Steven P. Treon and
  • Jorge J. Castillo

15 November 2022

Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic disorder characterized by an IgM paraprotein. The clinical presentation of WM varies and can include common manifestations such as anemia and hyperviscosity, in addition to less comm...

  • Review
  • Open Access
3 Citations
5,263 Views
13 Pages

Update in Childhood Chronic Myeloid Leukemia

  • Fiorina Giona and
  • Simona Bianchi

5 November 2022

Chronic myeloid leukemia (CML) in childhood represents only 3% of newly diagnosed pediatric leukemia. The diagnostic hallmark of CML is the Philadelphia (Ph) chromosome, which derives from the fusion of the ABL1-oncogene located on chromosome 9 to th...

  • Review
  • Open Access
6,192 Views
14 Pages

First-Line Treatment of Waldenström’s Macroglobulinaemia: Considerations Based on the Dutch National Guideline

  • Karima Amaador,
  • Marie José Kersten,
  • Hein P. J. Visser,
  • Laurens Nieuwenhuizen,
  • Roelandt F. J. Schop,
  • Martine E. D. Chamuleau,
  • Gerjo A. Velders,
  • Monique C. Minnema and
  • Josephine Mathilde Iris Vos

26 October 2022

Waldenström macroglobulinemia (WM) is a rare B-cell Non-Hodgkin Lymphoma. There are only few prospective randomized clinical trials to guide treatment recommendations and there is no international consensus on a preferred first line treatment ap...

  • Review
  • Open Access
3,623 Views
15 Pages

Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?

  • Marina Deodato,
  • Anna Maria Frustaci,
  • Giulia Zamprogna,
  • Giulia Cotilli,
  • Roberto Cairoli and
  • Alessandra Tedeschi

23 October 2022

Waldenström Macroglobulinemia (WM) is a rare indolent lymphoma with heterogeneous clinical presentation. As there are no randomised trials suggesting the best treatment option in treatment-naive patients, guidelines suggest either rituximab-comb...

  • Feature Paper
  • Review
  • Open Access
6 Citations
13,561 Views
26 Pages

Polyneuropathy Associated with IgM Monoclonal Gammopathy; Advances in Genetics and Treatment, Focusing on Anti-MAG Antibodies

  • Johannes P. M. van de Mortel,
  • Shirley D’Sa,
  • Alexander F. J. E. Vrancken,
  • Nicolette C. Notermans,
  • Josephine M. I. Vos and
  • Monique C. Minnema

17 October 2022

With increasing age, the chances of developing either MGUS or polyneuropathy increase as well. In some cases, there is a causative relationship between the IgM M-protein and polyneuropathy. In approximately half of these cases, IgM targets the myelin...

  • Feature Paper
  • Review
  • Open Access
2 Citations
7,772 Views
13 Pages

Transformed Waldenström Macroglobulinemia: Update on Diagnosis, Prognosis and Treatment

  • Eric Durot,
  • Cécile Tomowiak,
  • Elise Toussaint,
  • Pierre Morel,
  • Dipti Talaulikar,
  • Prashant Kapoor,
  • Jorge J. Castillo and
  • Alain Delmer

12 October 2022

Histological transformation (HT) to an aggressive lymphoma results from a rare evolution of Waldenström macroglobulinemia (WM). A higher incidence of transformation events has been reported in MYD88 wild-type WM patients. HT in WM can be histolo...

  • Feature Paper
  • Review
  • Open Access
1 Citations
3,904 Views
16 Pages

B Lymphoproliferative Neoplasms of Uncertain Biological Significance: Report from the IV Workshop of the Italian Group of Hematopathology and Review of the Literature

  • Gioia Di Stefano,
  • Francesca Magnoli,
  • Massimo Granai,
  • Federico Vittone,
  • Raffaella Santi,
  • Domenico Ferrara,
  • Emanuela Boveri,
  • Ada M. Florena,
  • Falko Fend and
  • the Italian Group of Hematopathology
  • + 6 authors

3 October 2022

Lymphoproliferative neoplasms of uncertain biological significance are increasingly encountered due to widespread usage of immunophenotypic and molecular techniques. Considering that clearer biological criteria and patient management have been establ...

  • Review
  • Open Access
3 Citations
6,024 Views
19 Pages

Genetics of Transformed Follicular Lymphoma

  • Miguel Alcoceba,
  • María García-Álvarez,
  • Jessica Okosun,
  • Simone Ferrero,
  • Marco Ladetto,
  • Jude Fitzgibbon and
  • Ramón García-Sanz

1 October 2022

Histological transformation (HT) to a more aggressive disease–mostly diffuse large B-cell lymphoma–is considered one of the most dismal events in the clinical course of follicular lymphoma (FL). Current knowledge has not found a single bi...

  • Feature Paper
  • Review
  • Open Access
10 Citations
9,650 Views
20 Pages

Molecular Pathogenesis of Follicular Lymphoma: From Genetics to Clinical Practice

  • Cristina López,
  • Pablo Mozas,
  • Armando López-Guillermo and
  • Sílvia Beà

26 September 2022

Follicular lymphoma (FL), a generally indolent disease that derives from germinal center (GC) B cells, represents around 20–25% of all new lymphomas diagnosed in Western countries. The characteristic t(14;18)(q32;q21) translocation that places...

  • Feature Paper
  • Review
  • Open Access
14 Citations
18,565 Views
21 Pages

Cold Agglutinin Disease: Improved Understanding of Pathogenesis Helps Define Targets for Therapy

  • Sigbjørn Berentsen,
  • Shirley D’Sa,
  • Ulla Randen,
  • Agnieszka Małecka and
  • Josephine M. I. Vos

20 September 2022

The last 2 decades have seen great progress in understanding the pathogenesis of cold agglutinin disease (CAD) and development of effective therapies. Cold agglutinins can cause hemolytic anemia as well as peripheral circulatory symptoms such as acro...

XFacebookLinkedIn
Hemato - ISSN 2673-6357